Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 4/20 | 1.00 |
| ▸ | RAF1 | P04049 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.60 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.60 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.60 |
| ▸ | PRKCG | P05129 | 2/20 | 0.60 |
| ▸ | PRKCB | P05771 | 2/20 | 0.60 |
| ▸ | CDK1 | P06493 | 2/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.60 |
| ▸ | PRKCA | P17252 | 2/20 | 0.60 |
| ▸ | PRKCH | P24723 | 2/20 | 0.60 |
| ▸ | PRKCI | P41743 | 2/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.60 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.60 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spongiacidin D SCHEMBL15426068 | 0.76 | CDK5 (1.00) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| SCHEMBL15230864 | 0.74 | MAPK1 (0.59) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| Hymenialdisine SCHEMBL24393900 | 0.74 | CDK5 (0.76) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| Hymenialdisine SCHEMBL18114524 | 0.73 | CDK5 (1.00) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| SCHEMBL3987882 | 0.73 | CDK5 (0.63) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| Hymenialdisine SCHEMBL15426167 | 0.73 | CDK5 (1.00) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| SCHEMBL5553646 | 0.71 | MAPK1 (0.56) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| Hymenialdisine SCHEMBL1249686 | 0.71 | CHEK2 (0.74) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| Hymenialdisine SCHEMBL155899 | 0.71 | CHEK2 (0.74) | MAP2K1RAF1MAPK1CDK5CDK5R1 | |
| Hymenialdisine SCHEMBL1249687 | 0.71 | CHEK2 (0.74) | MAP2K1RAF1MAPK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | PHARMACOSMOS HOLDING A/S (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-27 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20170135960-A1 | AGGREGATING MICROPARTICLES FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| WO-2017083779-A1 | AGGREGATING MICROPARTICLES FOR THERAPY | Graybug Vision, Inc. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2016182904-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016126889-A1 | CDK4/6 INHIBITOR DOSAGE FORMULATIONS FOR THE PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160220569-A1 | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2016040848-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-0711773-B1 | HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE | SUNTORY LTD (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-5621099-A | CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0711773-A1 | HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE | SUNTORY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | MAP2K1 2217/4885RAF1 2086/4885MAPK1 4256/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | MAP2K1 2428/4885RAF1 569/4885MAPK1 3925/4885 |
| US-20170135960-A1 | AGGREGATING MICROPARTICLES FOR MEDICAL THERAPY | MIF, VEGFA, ICAM1 | MAP2K1 4608/4885RAF1 4315/4885MAPK1 3303/4885 |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CCNO, CDK2, CCNI | MAP2K1 482/4885RAF1 268/4885MAPK1 526/4885 |
| US-20160220569-A1 | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy | CDK4, CDK6, CCNC | MAP2K1 490/4885RAF1 635/4885MAPK1 352/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | MAP2K1 2608/4885RAF1 178/4885MAPK1 2341/4885 |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | CTNND1, FLT3, MEF2D | MAP2K1 14/4885RAF1 73/4885MAPK1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.